Berns and colleagues showed enhanced tumorigenicity and expanded tumor spectrum in mice null for p15Ink4b and p16Ink4a/Arf, compared to p16Ink4a/Arf alone (Krimpenfort et al., 2007). The gene discussed is CDKN2A; the disease is neoplasm.